Compare · EXEL vs OKYO
EXEL vs OKYO
Side-by-side comparison of Exelixis Inc. (EXEL) and OKYO Pharma Limited (OKYO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EXEL and OKYO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- EXEL is the larger of the two at $16.71B, about 288.2x OKYO ($58.0M).
- EXEL has been more active in the news (7 items in the past 4 weeks vs 4 for OKYO).
- EXEL has more recent analyst coverage (25 ratings vs 2 for OKYO).
- Company
- Exelixis Inc.
- OKYO Pharma Limited
- Price
- -
- -
- Market cap
- $16.71B
- $58.0M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2022
- News (4w)
- 7
- 4
- Recent ratings
- 25
- 2
Exelixis Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
OKYO Pharma Limited
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. It is developing OK-101 for the treatment of dry eye disease; and OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. The company is also developing chemerin and chemerin analogues to treat the cytokine release syndrome associated with COVID-19 infections and other conditions, such as acute respiratory distress syndrome. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Latest EXEL
- Kernal Bio Announces Strategic Investment from IFLI and Leadership Appointments
- SEC Form SCHEDULE 13G filed by Exelixis Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Exelixis Inc.
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
- SEC Form 10-Q filed by Exelixis Inc.
- SEC Form 8-K filed by Exelixis Inc.
- Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
- Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- Exelixis Inc. filed SEC Form 8-K: Other Events
Latest OKYO
- SEC Form 6-K filed by OKYO Pharma Limited
- OKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in London
- SEC Form 6-K filed by OKYO Pharma Limited
- OKYO Pharma to Present at the Stifel 2026 Healthcare Conference
- SEC Form 6-K filed by OKYO Pharma Limited
- OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
- SEC Form 6-K filed by OKYO Pharma Limited
- OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
- SEC Form 6-K filed by OKYO Pharma Limited
- OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026